Categories AlphaGraphs, Earnings, Retail
Earnings preview: What to watch during American Eagle Outfitters’ Q1 2019 results
American Eagle Outfitters Inc. (NYSE: AEO) is scheduled to report first quarter 2019 earnings results on Wednesday, June 5, before market open. Earnings is estimated to decline 8.7% year-over-year to $0.21 per share while revenue is projected to increase nearly 4% to $855 million.
The company has consistently topped earnings forecasts for the trailing four quarters and can be expected to continue this trend in the first quarter as well. American Eagle’s top line results in the first quarter are likely to benefit from the company’s significant investments in its store network and digital channels.
The retailer has seen strong comparable sales growth over the past several quarters and expects comp sales to increase in the low single digits for the first quarter. American Eagle has been seeing healthy growth in its brands and this strength is expected to boost the company’s performance in the first quarter. However, higher expenses could impact margins negatively.
In the fourth quarter, American Eagle beat earnings estimates while revenues fell short. Revenues inched up by 1% to $1.24 billion while adjusted EPS was $0.44. Comparable sales rose 6%. For the Aerie brand, comp sales grew 23% while for the AE brand, they grew 3%.
For the first quarter of 2019, the company has guided for EPS to be around $0.19 to $0.21. At the end of fiscal 2019, American Eagle expects its store count to be in the range of 1,072 to 1,092 stores.
American Eagle’s shares have fallen 5% so far this year and over 20% in the trailing 52 weeks.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training